LIDEX-E Drug Patent Profile
✉ Email this page to a colleague
When do Lidex-e patents expire, and when can generic versions of Lidex-e launch?
Lidex-e is a drug marketed by Alvogen and is included in one NDA.
The generic ingredient in LIDEX-E is fluocinonide. There are nine drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lidex-e
A generic version of LIDEX-E was approved as fluocinonide by COSETTE on December 2nd, 1988.
Summary for LIDEX-E
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 72 |
Patent Applications: | 4,712 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LIDEX-E at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LIDEX-E
US Patents and Regulatory Information for LIDEX-E
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alvogen | LIDEX-E | fluocinonide | CREAM;TOPICAL | 016908-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LIDEX-E
See the table below for patents covering LIDEX-E around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
France | 2013281 | ⤷ Try a Trial | |
Germany | 1934334 | ⤷ Try a Trial | |
Sweden | 363975 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |